Golgi protein 73 (GP73) as a novel serum marker for early detection of hepatocellular carcinoma in Egyptian patients

Life Science Journal

Volumn 9, Issue 2, 2012, Pages 823-830

  El Shafie, Mona A ^a   Fawzy, Amal M ^b   Al Monem, Elhamy Abd ^a   Abbass, Sherif ^c   Zakaria, Doaa M ^d   El Baz, Sherif ^e  

^a MENOUFIA UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c MENOUFIA UNIVERSITY   (Egypt)

^d AL AZHAR UNIVERSITY   (Egypt)

^e NONE

Author keywords

AFP; DCP; ELISA; Golgi protein 73; HCC

Indexed keywords

EID: 84874871357     PISSN: 10978135     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. El-Serag HB, Rudolph KL (2007): Hepatocellular carcinoma: epidemiology andmolecular carcinogenesis. Gastroenterology, 132: 2557-2576.
2. Altekruse SF, McGlynn KA, Reichman ME (2009): Hepatocellular carcinoma, incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol, 27: 1485-1491.
3. Nguyen MH, Whittemore AS, Garcia RT, et al (2004): Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis. Clin Gastroenterol Hepatol, 2: 820-824.
4. Farazi PA, DePinho RA (2006): Hepatocellular carcinoma pathogenesis: from genes to environment. Na Rev Cancer, 6: 674-687.
5. El-Serag HB (2007): Epidemiology of hepatocellular carcinoma in USA. Hepatol Res, 37 (Suppl-2): S88-94.
6. El-Serag HB (2004): Hepatocellular carcinoma: recent trends in the United States. Gastroenterology, 127: S27-34.
7. Di Bisceglie AM and Hoofnagle JH. (1989): Elevations in serum α-fetoprotein levels inpatients with chronic hepatitis B. Cancer; 64: 2117-20.
8. Sherman M. Hepatocellular carcinoma (2005): epidemiology, risk factors, and screening. Semin Liver Dis; 25: 143-54.
9. Liebman HA, Furie BC, Tong MJ, et al. (1984): Desgamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med; 310: 1427-1431.
10. Weitz IC, Liebman HA. (1993): Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Hepatology; 18: 990-997.
11. Kladney RD, Bulla GA, Guo L, Mason AL, Tollefson AE, Simon DJ, et al. (2000): GP73, a novel Golgi-localized protein upregulated by viral infection. Gene; 249: 53-65.
12. Iftikhar R, Kladney RD, Havlioglu N, Solomon H, et al. (2004): Disease-and cell-specific expression of GP73 in human liver disease. Am J Gastroenterol; 99: 1087-1095.
13. Bachert C, Fimmel C, Linstedt AD. (2007): Endosomal trafficking and proprotein convertase cleavage of cis Golgi protein GP73 produces marker for hepatocellular carcinoma. Traffic; 8: 1415-1423.
14. Gu Y, Chen W, Zhao Y, Chen L, Peng T. (2009): Quantitative analysis of elevated serum Golgi protein-73 expression in patients with liver diseases. Ann Clin Biochem; 46: 38-43.
15. Block TM, Comunale MA, Lowman M, et al. (2005): Use of targeted glycopro-teomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci USA; 102: 779-784.
16. Marrero JA, Romano PR, Nikolaeva O, Steel L, Mehta A, Fimmel CJ, et al. (2005): GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol; 43: 1007-1012.
17. Marrero JA and Lok AS. (2004): Newermarkers for hepatocellular carcinoma. Gastroenterology; 127 (5 Suppl 1): S113-119.
18. Mao Y, Yang H, Xu H, Lu X, et al. (2010): Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut, doi10. 1136/gut. 2010. 214916.
19. Soresi M, Magliarisi C, Campagna P, et al. (2003): Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res; 23: 1747-1753
20. Li H, Wetten S, Li L, St Jean PL, Upmanyu R, Surh L, et al. (2008): Candidate single nucleotide polymorphisms from a genome wide association study of Alzheimer disease. Arch Neurol; 65: 45-53.
21. Marrero JA, Romano PR, Nikolaeva O, Fimmel CJ, et al. (2005): GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol; 43: 1007-1012.
22. Mao YL, Yang HY, Xu HF, et al. (2008): Significance of Golgi glycoprotein 73, a New tumour marker in diagnosis of hepatocellular carcinoma: a primary study. Zhonghua Yi Xue Za Zhi (In Chinese); 88: 948-951
23. Tian L, Wang Y, Xu D, Gui J, et al. (2010): Serological AFP/ golgi protein 73 could be a new diagnostic parameter of hepatic diseases. Int J Cancer Dec 7.
24. Riener MO, Stenner F, Liewen H et al. (2009): Golgi Phosphoprotein 2 (GOLPH2) Expression in Liver Tumors and Its Value as a Serum Marker in Hepatocellular Carcinomas. Hepatology;, 49: 1602-1609.
25. Block TM, Marrero J, Gish RG, Sherman M, London WT, Srivastava S, et al. (2008): The degree of readiness of selected biomarkers for the early detection of hepatocellular carcinoma: notes from a recent workshop. Cancer Biomark; 4: 19-33.
26. Puri S, Bachert C, Fimmel CJ, Linstedt AD. (2002): Cycling of early Golgi proteins via the cell surface and endosomes upon lumenal pH disruption. Traffic; 3: 641-653.
27. Chen TM, Huang PT, Tsai MH, Lin LF, Liu CC, Ho KS, et al. (2007): Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. J Gastroenterol Hepatol; 22: 669-675.
28. Norton PA, Comunale MA, Krakover J, Rodemich L, Pirog N, D'Amelio A, et al. (2008): N-linked glycosylation of the liver cancer biomarker GP73. J Cell Biochem; 104: 136-149.
29. Fimmel and Wright. (2009): Golgi Protein 73 as a Biomarker of Hepatocellular Cancer: Development of a Quantitative Serum Assay and Expression Studies in Hepatic and Extrahepatic Malignancies. Hepatology, Vol. 49, No. 5,: 1421-1423.
30. Hakamada K, Kimura N, Morohashi H et al. (2008): Des-gamma-carboxy prothrombin as an important prognostic indicator in patients with small hepatocellular carcinoma. World J Gastroenterol, March 7; 14 (9): 1370-1377.
31. Trevisani F, D'Intino PE, Morselli-Labate AM, et al. (2001): Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol; 34: 570-575.
32. Gambarin-Gelwan M, Wolf DC, Shapiro R, et al. (2000): Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. Am J Gastroenterol; 95: 1535-1538.
33. Durazo FA, Blatt LM, Corey WG, Lin JH, et al., (2008): Des-γ-carboxyprothrombin, α-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellularcarcinoma. J Gastroenterol Hepatol. Oct; 23 (10): 1541-8. Epub Apr 19.
34. Nakagawa T, Seki T, Shiro T, Wakabayashi M, et al. (1999): Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma. Int J Oncol; 14: 281-286.
35. Sterling RK, Jeffers L, Gordon F, Sherman M, et al. (2007): Clinical utility of AFP-L3 measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol; 102: 2196-2205.
36. Sterling RK, Jeffers L, Gordon F, et al. (2009): Utility of Lens culinaris agglutinin-reactive fraction of alphafetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin Gastroentero-Hepatol; 7: 104-113.
37. Gomaa AI, Khan SA, Leen EL, Waked I, Taylor-Robinson SD. (2009): Diagnosis of hepatocellular carcinoma. World J Gastroenterol; 15 (11): 1301-1314.
38. Wang M, Long RE, Comunale MA, Junaidi O et al. (2009): Novel Fucosylated Biomarkers for the Early Detection of Hepatocellular Carcinoma. Cancer Epidemiol Biomarkers Prev; 18: 1914-1921.
39. Sangiovanni A, Romeo R, Prati GM, Manini MA, et al. (2007): Serum expression of lectin reactive alphafetoprotein, des-gammacarboxy prothrombin, golgi protein-73 antigen and antibody, for the diagnosis of hepatocellular carcinoma [Abstract]. Hepatology,; 46 (Suppl): 406A.
40. Anderson NL and Anderson NG. (2002): The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics; 1: 845-867.
41. Sun Y, Yang H, Mao Y et al. (2011): Increased GP73 expression in hepatocellular carcinoma tissue correlates with tumor aggression but not survival. Journal of Gastroenterol Hepatol; 26 (7): 1207-12. doi: 10. 1111/j. 1440-1746. 2011. 06733. x.